METHYLGENE TO PRESENT AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING
Montreal, Quebec. March 28, 2012 – MethylGene Inc. (TSX:MYG) today announced that preclinical data for its multi-targeted kinase inhibitor, MGCD265, will be reported in a poster session at the 2012 American Association for Cancer Research (AACR) Annual Meeting to be held in Chicago, Illinois from March 31 to April 4, 2012. The poster will highlight novel mechanisms underlying anti-tumor activity observed when MGCD265 is combined with erlotinib, an inhibitor of EGFR.
In another session on science policy, MethylGene’s Chief Medical Officer, Dr. Rachel Humphrey, will give a presentation on the use of biomarkers in clinical development.
The Combination of MGCD265, a Met/VEGFR Inhibitor in Clinical Development, and Erlotinib Potently Inhibits Tumor Growth by Altering Multiple Pathways Including Glycolysis
Date and Time: Monday Apr 2, 2012 8:00 AM – 12:00 PM (CT)
Session: Experimental and Molecular Therapeutics 11
Abstract No.: 1790
Location: Hall F, Poster Section 29
Science Policy Session
Dr. Humphrey’s presentation is entitled “Biomarkers in clinical development: Strategic considerations”.
Date and Time: Monday Apr 2, 2012 1:30 – 1:50 PM (CT)
Session: SP03. Scientific and Regulatory Challenges in Codevelopment of Predictive In Vitro Diagnostics
Location: McCormick Place South (Level 1), Room S103
MGCD265 is a novel, oral small molecule inhibitor that targets a unique spectrum of receptor tyrosine kinases: Met, VEGFR 1, 2, and 3, Tie-2 and Ron. These kinases play key roles in tumor development, survival and metastasis as well as the inappropriate formation of blood vessels (angiogenesis) that nourish the tumor. MGCD265 has completed one Phase 1 single agent study, and is nearing completion of one Phase 1 single agent clinical trial and one Phase 1/2 combination clinical trial (with erlotinib and docetaxel) in solid tumors.
MethylGene Inc. (TSX:MYG) is a small molecule drug development company that is advancing two novel therapeutics for cancer and infectious disease in human clinical trials. The Company’s lead product candidates are: MGCD290, an oral antifungal agent targeting the fungal Hos2 enzyme that is currently in Phase 2 trials for vulvovaginal candidiasis, and MGCD265, an oral Met/VEGF receptor kinase inhibitor that is in Phase 1/2 clinical trials for solid tumor cancers. MethylGene owns all rights to its lead product candidates, and has partnerships with Otsuka Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and EnVivo Pharmaceuticals, Inc. for its other pipeline programs.